Mirtazapina Flas Cinfamed (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This combined action enhances serotonergic and noradrenergic neurotransmission while providing a sedative effect through histamine blockade.

The appropriate dose of mirtazapine is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage decisions are made by a qualified healthcare professional and are not standardized in product literature.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in strong sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those prone to weight gain.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Mirtazapina Flas Cinfamed is taken orally, usually once daily in the evening to take advantage of its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hypersensitivity reactions, emergence or worsening of suicidal thoughts, hepatotoxicity, seizures, and serotonin syndrome when combined with other serotonergic agents. Patients should be monitored closely for any of these events.

Mirtazapine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and in those currently taking monoamine oxidase inhibitors. Caution is also advised for individuals with severe hepatic impairment, uncontrolled epilepsy, or a history of severe cardiac arrhythmias.